Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics

被引:110
作者
Patrick, K. S. [1 ]
Straughn, A. B.
Minhinnett, R. R.
Yeatts, S. D.
Herrin, A. E.
DeVane, C. L.
Malcolm, R.
Janis, G. C.
Markowitz, J. S.
机构
[1] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA
[2] Univ Tennessee, Dept Pharmaceut, Memphis, TN 38163 USA
[3] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA
[4] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
[5] MEDTOX Labs, St Paul, MN USA
关键词
D O I
10.1038/sj.clpt.6100082
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explores the hypotheses that: (1) ethanol will interact with di-Methylphenidate (MPH) to enantioselectively elevate plasma d-MPH, and primarily yield l-ethylphenidate as a transesterification metabolite; (2) women will exhibit lower relative bioavailability of MPH than men; and (3) sex-dependent differences in subjective effects will exist. dI-MPH HCl (0.3 mg/kg) was administered orally 30 min before ethanol, 30 min after ethanol (0.6 gm/kg), or without ethanol, in a randomized, normal subject three-way crossover study of 10 men and 10 women. Pharmacokinetic parameters were compared. Subjective effects were recorded using visual analog scales. One subject was a novel poor MPH metabolizer whose data were analyzed separately. Ethanol after or before MPH significantly (P < 0.0001) elevated the geometric mean for the maximum d-MPH plasma concentration (C-max (+/- SD)) from 15.3 (3.37) ng/ml to 21.5 (6.81) and 21.4 (4.86), respectively, and raised the corresponding geometric mean for the area under the concentration-time curve values from 82.9 (21.7) ng ml/h to 105.2 (23.5) and 102.9 (19.2). I-MPH was present in plasma only at 1-3% of the concentration of d-MPH, except in the poor metabolizer where I-MPH exceeded that of d-MPH. The metabolite l-ethylphenidate frequently exceeded 1 ng/ml in plasma, whereas d-ethylphenidate was detected only in low pg/ml concentrations. Women reported a significantly greater stimulant effect than men when questioned "Do you feel any drug effect?" (P < 0.05), in spite of lower mean plasma d-MPH area under the response-time curves in women. Ethanol elevates plasma d-MPH C-max and area under the concentration-time curve by approximately 40% and 25%, respectively. If the poor metabolizer of MPH proves to be a distinct phenotype, determining the genetic mechanism may be of value for individualizing drug therapy. The more pronounced stimulant effects experienced by women have sex-based abuse liability implications.
引用
收藏
页码:346 / 353
页数:8
相关论文
共 31 条
[1]   Oral methylpherlidate-alcohol co-abuse [J].
Barrett, SP ;
Pihl, RO .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) :633-634
[2]  
BIEDERMAN J, 1995, AM J PSYCHIAT, V152, P1652
[3]  
Biederman J, 2002, J Atten Disord, V6 Suppl 1, pS101
[4]   Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users [J].
Heil, SH ;
Holmes, HW ;
Bickel, WK ;
Higgins, ST ;
Badger, GJ ;
Laws, HF ;
Faries, DE .
DRUG AND ALCOHOL DEPENDENCE, 2002, 67 (02) :149-156
[5]  
JAFFE SL, 1991, J AM ACAD CHILD PSY, V30, P773, DOI 10.1016/S0890-8567(10)80014-0
[6]   Alcohol plus cocaine: The whole is more than the sum of its parts [J].
Jatlow, P ;
McCance, EF ;
Bradberry, CW ;
Elsworth, JD ;
Taylor, JR ;
Roth, RH .
THERAPEUTIC DRUG MONITORING, 1996, 18 (04) :460-464
[7]   Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder [J].
Jonkman, LM ;
Verbaten, MN ;
de Boer, D ;
Maes, RAA ;
Buitelaar, JK ;
Kemner, C ;
van Engeland, H ;
Koelega, HS .
PSYCHIATRY RESEARCH, 1998, 78 (1-2) :115-118
[8]   Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate [J].
Kollins, SH ;
Rush, CR ;
Pazzaglia, PJ ;
Ali, JA .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 1998, 6 (04) :367-374
[9]   Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder [J].
Levin, FR ;
Evans, SM ;
Kleber, HD .
PSYCHIATRIC SERVICES, 1999, 50 (08) :1001-1003
[10]   Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations [J].
Markowitz, JS ;
Straughn, AB ;
Patrick, KS .
PHARMACOTHERAPY, 2003, 23 (10) :1281-1299